Abstracts Archive - Page 1388 of 2425 - ACR Meeting Abstracts

Abstract Number: 2737 • 2017 ACR/ARHP Annual Meeting
Pulmonary Manifestations of Primary Systemic Vasculitides
Jean-Paul Makhzoum¹, Raashid Luqmani², Richard A. Watts³, Anthea Craven⁴, Peter A. Merkel⁵ and Christian Pagnoux⁶, ¹Rheumatology, Vasculitis Clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³Rheumatology Department, The Ipswich Hospital, Ipswich, Great Britain, ⁴Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Oxford University Hospitals, Oxford, United Kingdom, ⁵Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁶Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Pulmonary involvement in systemic primary vasculitides is diverse and occurs with variable incidence depending on the type of vasculitis. This study aimed to describe…
Abstract Number: 2738 • 2017 ACR/ARHP Annual Meeting
Infectious Complications in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials
Lafarge Antoine¹, Christian Pagnoux², Xavier Puéchal³, Maxime Samson⁴, Mohamed Hamidou⁵, Alexandre Karras⁶, Thomas Quémeneur⁷, Matthieu Groh⁸, Luc Mouthon⁹, Loïc Guillevin for the French Vasculitis Study Group³ and Benjamin Terrier¹⁰, ¹Medecine Interne, Hôpital Cochin, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Medecine Interne, CHU Hôtel Dieu, Nantes, France, ⁶nephrology, HEGP, Paris, France, ⁷Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁹Université Paris Descartes Sorbonne Paris, Paris, France, ¹⁰Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: Prognosis of patients with systemic necrotizing vasculitides has been markedly improved during the last 2 decades. However, infectious complications remain a major cause of…
Abstract Number: 2739 • 2017 ACR/ARHP Annual Meeting
Onco-Hematological Malignancies in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials
Lafarge Antoine¹, Christian Pagnoux², Xavier Puéchal³, Maxime Samson⁴, Mohamed Hamidou⁵, Alexandre Karras⁶, Thomas Quémeneur⁷, Matthieu Groh⁸, Luc Mouthon⁹, Loïc Guillevin for the French Vasculitis Study Group³ and Benjamin Terrier¹⁰, ¹Medecine Interne, Hôpital Cochin, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Medecine Interne, CHU Hôtel Dieu, Nantes, France, ⁶nephrology, HEGP, Paris, France, ⁷Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁹Université Paris Descartes Sorbonne Paris, Paris, France, ¹⁰Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: The use of long-term immunosuppressive agents in patients with systemic necrotizing vasculitides has dramatically improved the overall prognosis, but expose patients to potential severe…
Abstract Number: 2740 • 2017 ACR/ARHP Annual Meeting
Cyclophosphamide Treatment Modulates Circulating Cell Populations in Patients with Vasculitis and Autoimmune Systemic Diseases
Martina Skácelová¹, Gabriela Gabčová², Pavel Horak³, Zuzana Mikulková², František Mrázek⁴, Eva Kriegová⁵ and Andrea Smržová⁶, ¹III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ²Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic, ³III. Department of internal medicine, III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ⁴Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ⁵Department of Immunology, Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ⁶III. Department of Internal Medicine, III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic
Background/Purpose: Although cyclophosphamide (CFA) remain the cornerstone for treatment of patients with severe manifestations of systemic autoimmune diseases, the knowledge about the effect of CFA…
Abstract Number: 2741 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Factor (RF) Levels Remain Persistently Elevated 24 Weeks after Interferon (INF) Free Direct Antiviral Agents (DAA) Therapy in the Majority of RF+ HCV Infected Persons
Corinne Kowal¹, Carey Shive^2,3, Elizabeth Zebrowski^4,5, Lenche Kostadinova^1,6, Brianna Fuller^1,6, Elane Reyes², Kelsey Rife⁴, Amy Hirsch⁴, Anita Compan⁴, Shyam Kottilil⁷, Yngve Falck-Ytter^6,8, Leonard H. Calabrese⁹, Donald Anthony^4,6,10,11 and Maya Mattar^6,12, ¹Department of Medicine, Louis Stokes VA Medical Center, Cleveland, OH, ²Department of Medicine and Pathology, Case Western Reserve University, Cleveland, OH, ³VA Geriartic Research and Education Clinical Center (GRECC), Louis Stokes VA Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Cleveland, OH, ⁵Department of Medicine, Case Western Reserve University, Cleveland, OH, ⁶Case Western Reserve University, Cleveland, OH, ⁷IHV Clinical Research Unit, University of Maryland, Baltimore,, Baltimore, MD, ⁸Internal Medicine/ Division of gastroenterology, Louis Stokes VA Medical Center, Cleveland, OH, ⁹Rheumatic & Immunologic Disease and Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, ¹⁰Division of Medicine and Pathology, Divisions of Infectious and Rheumatic diseases, University Hospitals Cleveland Medical Center, Cleveland, OH, ¹¹VA Geriatric Research and Education Clinical Center (GRECC), Cleveland, OH, ¹²Internal Medicine/ Division of Rheumatology, University Hospitals Cleveland Medical Center, Cleveland, OH
Background/Purpose: Cryoglobulinemic vasculitis (CV) is an extrahepatic manifestation of chronic HCV infection. It varies in severity from mild to life threatening. Some but not all…
Abstract Number: 2742 • 2017 ACR/ARHP Annual Meeting
A Retrospective Study Comparing the Phenotype and Outcomes of Patients with Polyarteritis Nodosa between UK and Turkish Cohorts
Omer Karadag^1,2, Abdulsamet Erden², Yelda Bilginer², Seerapani Gopaluni¹, Alper Sari², Berkan Armagan², Ihsan Ertenli², Seza Ozen² and David Jayne³, ¹Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom, ²Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ³Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Polyarteritis Nodosa (PAN) is a rare subgroup of the primary vasculitides. There are only two published cohorts describing demographic and clinical features of the disease.…
Abstract Number: 2743 • 2017 ACR/ARHP Annual Meeting
Requirement and Response Rates of Biologic Agents in Polyarteritis Nodosa (PAN)
Omer Karadag^1,2, Berkan Armagan², Abdulsamet Erden², Seerapani Gopaluni¹, Alper Sari², Sedat Kiraz² and David Jayne³, ¹Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom, ²Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ³Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Recent studies highlight the usefulness and necessity of biologic agents in the treatment of primary vasculitides. Evidence for the use of biologics in PAN…
Abstract Number: 2744 • 2017 ACR/ARHP Annual Meeting
Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment
Petros P Sfikakis¹, Aikaterini Arida¹, Stylianos Panopoulos², Kalliopi Fragkiadaki², George Pentazos³, Katerina Laskari³, Maria Tektonidou¹ and Nikos Markomichelakis², ¹First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, athens, Greece, ²First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, ³Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece
Background/Purpose: Anti-TNF treatment has been shown to be effective in inducing complete remission in many Behcet’s disease (BD) patients with eye, large vessel, intestine and…
Abstract Number: 2745 • 2017 ACR/ARHP Annual Meeting
Prevalence of Vasculitides As Extraintestinal Manifestation of Inflammatory Bowel Disease (IBD)
Sarah Ifteqar¹, Jason Springer² and Mehrdad Maz³, ¹Department of Medicine, Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS, ³Allergy, Clinical Immunology, and Rheumatology, Division of Allergy, Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: The extraintestinal manifestations of Inflammatory Bowel Disease (IBD) are identified in 6%-40% of patients. Systemic vasculitides may present as extraintestinal manifestations of IBD. The purpose…
Abstract Number: 2746 • 2017 ACR/ARHP Annual Meeting
Comparison between IgG and IgM Type Anti-Alpha-Enolase Antibody in Patients with Behcet’s Disease According to the Disease Severity
Shin Eui Kang¹, Sang Jin Lee^1,2, Hyun Jung Yoo^1,3, Jeong Yeon Kim¹, Ji Soo Park¹, Sehui Shon⁴, Eun Young Lee³, Eun Bong Lee³ and Yeong Wook Song^1,3, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁴Department of Molecular Medicine and Biopharmaceutical Sciences, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Behcet’s disease (BD) is a chronic inflammatory disease of unknown etiology, characterized by recurrent oral and genital ulcers, skin lesions, uveitis, and arthritis. It…
Abstract Number: 2747 • 2017 ACR/ARHP Annual Meeting
Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide
Mert Gurcan¹, Sinem Nihal Esatoglu¹, Vedat Hamuryudan¹, Caner Saygin², Didem Saygin³, Serdal Ugurlu⁴, Emire Seyahi¹, Melike Melikoglu¹, Izzet Fresko¹, Sebahattin Yurdakul¹, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Cleveland, OH, ³Internal Medicine, Department of Internal Medicine, Cleveland Clinic, Cleveland, Cleveland, OH, ⁴Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Cyclophosphamide (CYC) remains an important treatment option for Behçet’s syndrome (BS) pts with life threatening conditions such as arterial aneurysms. However, several adverse events…
Abstract Number: 2748 • 2017 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study
Sinem Nihal Esatoglu¹, Fatma Nihan Akkoc¹, Yesim Ozguler¹, Fatma Ozbakir², Okan Kadir Nohut², Dilsen Cevirgen³, Vedat Hamuryudan¹, Ibrahim Hatemi⁴, Aykut Ferhat Celik⁵, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Central Research Laboratory, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of and Rheumatology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Immunogenicity of anti-TNFs has been recognized as an important problem that may cause loss of response and adverse events such as infusion reactions. We…
Abstract Number: 2749 • 2017 ACR/ARHP Annual Meeting
Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries
Tsuyoshi Shirai¹, Hiroshi Fujii¹, Yoko Fujita², Yuko Shirota¹, Tomonori Ishii¹ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Polyarteritis nodosa (PAN) is a necrotizing arteritis of medium and small arteries. PAN is divided into systemic and cutaneous PAN (cPAN). cPAN can be…
Abstract Number: 2750 • 2017 ACR/ARHP Annual Meeting
A Serum Metabolomic Analysis in Behcet’s Disease: A Preliminary Study
Wenjie Zheng¹, Xiuhua Wu^1,2, Maryam Goudarzi³, Hua Chen¹, JinJing Liu¹, Jing Shi¹, Chaoran Li¹, Mengyu Zhou⁴, Wen Zhang¹, Xuan Zhang¹ and Henghong Li³, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Rheumatology, General Hospital of Tianjin Medical University, Tianjing, China, ³Georgetown University Medical Center, Georgetown University, Washington, DC, WA, ⁴Peking Union Medical College Hospital, Beijing, China
Background/Purpose: The diagnosis of Behçet's disease (BD) is mainly based on clinical manifestations and remains a challenge in clinical practice, due to the fact that…
Abstract Number: 2751 • 2017 ACR/ARHP Annual Meeting
Tocilizumab in the Treatment of Severe and/or Refractory Behcet’s Disease：a Single-Centre Experience in China
Wenjie Zheng¹, Yanxia Ding^1,2, Di Wu¹, Jiaxin Zhou¹, JinJing Liu¹, Dong Yan¹, Mengyu Zhou³, Yan Zhao¹ and Fengchun Zhang³, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Rheumatology, The First Affiliated Hospital of Zhengzhou, Zhengzhou, China, ³Peking Union Medical College Hospital, Beijing, China
Background/Purpose: To report the efficacy and safety of tocilizumab(TCZ) for the treatment of severe and/or refractory Behçet's disease(BD). Methods: We retrospectively analyzed the efficacy and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].